Loading video...

Video Failed to Load

Go Home

#Cabozantinib is now approved in #NET based off #CABINET study! We discussed the design, findings, sequencing, and AEs w/ Aman Chauhan Full 🗣️: ⭐️ ⭐️ Also on the “Oncology Brothers” podcast #OncTwitter #MedTwitter #gism #GiOnc

OncBrothers's profile picture

Oncology Brothers

17,715 subscribers

21,289 views • 1 year ago •via X (Twitter)

Health & WellnessNews & PoliticsScience & Technology#Cabozantinib#NET#CABINET#OncTwitter#MedTwitter#gism#GiOnc
LIVE

Anya Rossi• Live Now

Private livecam show

2 Comments

Sabine MD's profile picture
Sabine MD1 year ago

@AmanChauhanMD @SylvesterCancer @GlopesMd @NVijayvergiaMD @UGrewalMD @IMG_Oncologists @OncoThor @GrupoGetne @PancPathologist @rcarvalhoonco @T4Cancer The CABINET study’s real-world impact will be profound. How do you anticipate cabozantinib reshaping NET protocols? Eager for the podcast’s take on sequencing. #GiOnc #MedTwitter

Inc.'s profile picture
Inc.1 year ago

3 takeaways from our smarter spending podcast with @brexHQ CEO Pedro Franceschi. Number 1: Empower employees with proper fiscal authority. Learn more and listen to the podcast here. @pedroh96 #ad

Related Videos

#GISeries: #Zolbetuximab was approved based off #GLOW & #SPOTLIGHT! We discussed the design, findings, sequencing and AEs/management w/ Kohei shitara Full Discussion: ⭐️ ⭐️ Also on the “Oncology Brothers” podcast #OncTwitter #MedTwitter #gism
2:05

#GISeries: #Zolbetuximab was approved based off #GLOW & #SPOTLIGHT! We discussed the design, findings, sequencing and AEs/management w/ Kohei shitara Full Discussion: ⭐️ ⭐️ Also on the “Oncology Brothers” podcast #OncTwitter #MedTwitter #gism

Oncology Brothers

28,211 views • 1 year ago

DatoDXd is now approved for previously treated mEGFR NSCLC based off #TROPIONLung01 & 05! We had a chance to 🗣️ this trial, findings, AEs and sequencing w/ Jacob sands Full 🗣️: ⭐️ ⭐️ Also on “Oncology Brothers” podcast #OncTwitter #lcsm
1:03

DatoDXd is now approved for previously treated mEGFR NSCLC based off #TROPIONLung01 & 05! We had a chance to 🗣️ this trial, findings, AEs and sequencing w/ Jacob sands Full 🗣️: ⭐️ ⭐️ Also on “Oncology Brothers” podcast #OncTwitter #lcsm

Oncology Brothers

14,446 views • 11 months ago

Zongertinib is now approved for Her2+ NSCLC based off Beamion Lung-1! We had a chance to 🗣️ Her2 testing, trial, findings, AEs and sequencing w/ Joshua Sabari, MD Full 🗣️: ⭐️ ⭐️ Also on “Oncology Brothers” podcast #OncTwitter #lcsm OncUpdates
1:11

Zongertinib is now approved for Her2+ NSCLC based off Beamion Lung-1! We had a chance to 🗣️ Her2 testing, trial, findings, AEs and sequencing w/ Joshua Sabari, MD Full 🗣️: ⭐️ ⭐️ Also on “Oncology Brothers” podcast #OncTwitter #lcsm OncUpdates

Oncology Brothers

25,876 views • 11 months ago

Durvalumab (+FLOT) is now U.S. FDA ✅ for resectable Gastric & GEJ adenocarcinoma based off #MATTERHORN! We 🗣️ this trial, findings, PDL1, and AEs w/ Yelena Y. Janjigian MD Full 🗣️: ⭐️ ⭐️ Also on “Oncology Brothers” podcast OncoAlert OncUpdates #gism
1:10

Durvalumab (+FLOT) is now U.S. FDA ✅ for resectable Gastric & GEJ adenocarcinoma based off #MATTERHORN! We 🗣️ this trial, findings, PDL1, and AEs w/ Yelena Y. Janjigian MD Full 🗣️: ⭐️ ⭐️ Also on “Oncology Brothers” podcast OncoAlert OncUpdates #gism

Oncology Brothers

10,064 views • 8 months ago

Lurbinectedin is now approved in 1L for ES-SCLC based off #IMForte! We had a chance to discuss the trial, findings, AE's and management w/ Isabel Preeshagul Stephen V Liu, MD & Ticiana Batista (Leal) Full 🗣️: ⭐️ ⭐️ On “Oncology Brothers” podcast #OncTwitter #lcsm
0:58

Lurbinectedin is now approved in 1L for ES-SCLC based off #IMForte! We had a chance to discuss the trial, findings, AE's and management w/ Isabel Preeshagul Stephen V Liu, MD & Ticiana Batista (Leal) Full 🗣️: ⭐️ ⭐️ On “Oncology Brothers” podcast #OncTwitter #lcsm

Oncology Brothers

15,442 views • 10 months ago

GI Malignancies Conference Highlights from #ASCO26 w/ Namrata (Neena) Vijayvergia MD ✅ #EMERALD3 ✅ #FIGHT302 ✅ #CIRCULATE ✅ #MATTERHORN Full 🗣️ ⭐️ “Oncology Brothers” podcast ⭐️ #OncTwitter #MedTwitter #gism OncUpdates
2:04

GI Malignancies Conference Highlights from #ASCO26 w/ Namrata (Neena) Vijayvergia MD ✅ #EMERALD3 ✅ #FIGHT302 ✅ #CIRCULATE ✅ #MATTERHORN Full 🗣️ ⭐️ “Oncology Brothers” podcast ⭐️ #OncTwitter #MedTwitter #gism OncUpdates

Oncology Brothers

12,091 views • 1 month ago

HER2+ metastatic BTC Pt 3/3! Here we 🗣️ AEs, management, step down dosing for availabms Rx options (TDxD & Zanidatamab) w/ Rachna Shroff, MD, MS, FASCO Full 📢: 🌟 🌟 🌟Also on the “Oncology Brothers” podcast! #OncTwitter #MedTwitter #gism
0:51

HER2+ metastatic BTC Pt 3/3! Here we 🗣️ AEs, management, step down dosing for availabms Rx options (TDxD & Zanidatamab) w/ Rachna Shroff, MD, MS, FASCO Full 📢: 🌟 🌟 🌟Also on the “Oncology Brothers” podcast! #OncTwitter #MedTwitter #gism

Oncology Brothers

12,063 views • 1 year ago

In our “Challenging Cases” 🗣️ we touch on 2L & beyond for RCC w/ David Braun!“What next” after dual ICI or IO+TKI? ✅ Sequencing ✅ Data post IO ✅ AEs & management Full 🗣️: ⭐️ ⭐️ “Oncology Brothers” podcast #OncTwitter #gusm OncUpdates OncoAlert
1:10

In our “Challenging Cases” 🗣️ we touch on 2L & beyond for RCC w/ David Braun!“What next” after dual ICI or IO+TKI? ✅ Sequencing ✅ Data post IO ✅ AEs & management Full 🗣️: ⭐️ ⭐️ “Oncology Brothers” podcast #OncTwitter #gusm OncUpdates OncoAlert

Oncology Brothers

10,925 views • 8 months ago

Signing off 2025 on a positive note w/ a discussion around U.S. FDA approval of #Enfortumab + Pembro (EV303) in MIBC w/ Tom Powles (design, findings, AEs, role of ctDNA) Full 🗣️: ⭐️ ⭐️ “Oncology Brothers” podcast #BladderCancer OncUpdates OncoAlert
1:08

Signing off 2025 on a positive note w/ a discussion around U.S. FDA approval of #Enfortumab + Pembro (EV303) in MIBC w/ Tom Powles (design, findings, AEs, role of ctDNA) Full 🗣️: ⭐️ ⭐️ “Oncology Brothers” podcast #BladderCancer OncUpdates OncoAlert

Oncology Brothers

11,998 views • 7 months ago

GI Cancer Highlights from #ASCO25 w/ Dr. Cathy Eng ✅ #DYNAMIC3 ✅ #ATOMIC ✅ #BREAKWATER ✅ #MATTERHORN ✅ #DESTINYGastric04 Full Discussion: - - Also on the “Oncology Brothers” podcast #gism ASCO #OncTwitter #MedTwitter
1:43

GI Cancer Highlights from #ASCO25 w/ Dr. Cathy Eng ✅ #DYNAMIC3 ✅ #ATOMIC ✅ #BREAKWATER ✅ #MATTERHORN ✅ #DESTINYGastric04 Full Discussion: - - Also on the “Oncology Brothers” podcast #gism ASCO #OncTwitter #MedTwitter

Oncology Brothers

61,635 views • 1 year ago

ToxCheck: AEs for ADCs approved in Lung Cancer & how to manage them with Jacob sands: ✅ TDXd: HER2+ ✅ DatoDXd: EGFR+ ✅ TelisoV: C-MET Full 🗣️: ⭐️ ⭐️ Also on “Oncology Brothers” podcast #OncTwitter OncUpdates OncoAlert #lcsm
1:28

ToxCheck: AEs for ADCs approved in Lung Cancer & how to manage them with Jacob sands: ✅ TDXd: HER2+ ✅ DatoDXd: EGFR+ ✅ TelisoV: C-MET Full 🗣️: ⭐️ ⭐️ Also on “Oncology Brothers” podcast #OncTwitter OncUpdates OncoAlert #lcsm

Oncology Brothers

15,258 views • 7 months ago

#ToxCheck: AntiVEGF & AntiEGFR have been approved for years. Just before #GI25, w/ Pashtoon Kasi MD, MS we 🗣️ key AEs & management strategies for these drugs! Full 📢 ⭐️ ⭐️ “Oncology Brothers” podcast #OncTwitter #bevacizumab #panitumumab #cetuximab #crcsm
1:13

#ToxCheck: AntiVEGF & AntiEGFR have been approved for years. Just before #GI25, w/ Pashtoon Kasi MD, MS we 🗣️ key AEs & management strategies for these drugs! Full 📢 ⭐️ ⭐️ “Oncology Brothers” podcast #OncTwitter #bevacizumab #panitumumab #cetuximab #crcsm

Oncology Brothers

20,720 views • 1 year ago

As we gear up for #GI26, we discussed testing and the current SoC for HER2+ advanced/metastatic GEJ/Gastric cancer with Rutika Mehta: Full discussion: ⭐️ ⭐️ ⭐️ Also on “Oncology Brothers” podcast #lcsm #OncTwitter OncUpdates
1:19

As we gear up for #GI26, we discussed testing and the current SoC for HER2+ advanced/metastatic GEJ/Gastric cancer with Rutika Mehta: Full discussion: ⭐️ ⭐️ ⭐️ Also on “Oncology Brothers” podcast #lcsm #OncTwitter OncUpdates

Oncology Brothers

11,991 views • 7 months ago

Part 2/3 on SCLC! Here we discuss AEs and management of our available options in Extensive Stage small cell w/ Misty Dawn Shields Full 📢 🌟 🌟 🌟Also on the “Oncology Brothers” podcast #OncTwitter #MedTwitter #lcsm #CME
0:54

Part 2/3 on SCLC! Here we discuss AEs and management of our available options in Extensive Stage small cell w/ Misty Dawn Shields Full 📢 🌟 🌟 🌟Also on the “Oncology Brothers” podcast #OncTwitter #MedTwitter #lcsm #CME

Oncology Brothers

17,402 views • 11 months ago

Treatment Algorithm series: Discussion w/ Tim Brown, MD MSCE on GEJ/Gastric Adeno ✅ ESOPEC ✅ Adj Nivo ✅ Biomarkers: MSI, PDL1, HER2, CLDN18.2 Full 🔊: ⭐️ ⭐️ ⭐️ “Oncology Brothers” podcast #gism #OncTwitter CancerNetwork®
1:10

Treatment Algorithm series: Discussion w/ Tim Brown, MD MSCE on GEJ/Gastric Adeno ✅ ESOPEC ✅ Adj Nivo ✅ Biomarkers: MSI, PDL1, HER2, CLDN18.2 Full 🔊: ⭐️ ⭐️ ⭐️ “Oncology Brothers” podcast #gism #OncTwitter CancerNetwork®

Oncology Brothers

38,272 views • 1 year ago